Nexalin Technology Reports Improved Sleep Quality in Alzheimer’s Patients
Nexalin Technology, Inc. has announced the publication of a study demonstrating that their 15 mA DIFS™ technology significantly improves sleep quality in patients with mild Alzheimer’s disease. The randomized, double-blind, sham-controlled TRANSFORM-AD study revealed statistically significant improvements in sleep quality as measured by the Pittsburgh Sleep Quality Index, with no serious adverse events reported. This study is the first to evaluate high-intensity stimulation for neuropsychiatric symptoms in Alzheimer’s patients.
Results from the randomized, double-blind, sham-controlled TRANSFORM-AD study published in the Journal of Alzheimer’s Disease, a recognized international peer-reviewed journal
